With patients in mind, Traverse Biotech creates value by accelerating the development of clinically validated Ex-US medical innovations into the US market launching them into clinical application.
In partnership with leading international biotechnology companies located outside of the US (Ex-US), Traverse Biotech builds new companies nested within the New York City biotech ecosystem. Traverse Biotech provides full scale scientific, financial, and legal capacity to enable product development of a diversified pipeline. Through lean and agile management, Traverse can implement preclinical and clinical development capabilities immediately in a separate US financing vehicle.
An opportunity for US investors to access Ex-US Biotech Company innovations and to follow the development of their technology within a US C-Corp entity.
Traverse Biotech is aiming to become a preferred U.S. development partner to Ex-US Biotech companies that is focused on value creation around non-primary assets whose development is currently frozen due to corporate strategy or constrained resources. Each asset under development by Traverse Biotech will have clinical and manufacturing validation.
While the Ex-US company is focused on obtaining clinical success of their lead compounds, Traverse Biotech:
VALUE PROPOSITION FOR SELECTED Ex-US BIOTECH COMPANIES:
The Traverse Biotech value creation model selectively works with Ex-US biotech companies to launch promising preclinical assets into clinical application in high unmet medical need spaces
SGC provides clinical and medical expertise for patient-focused drug and vaccine development, approval and launch programs.
VCLS is dedicated to supporting clients from discovery to patients. Their healthech product specialists offer integration solutions to development planning, manufacturing, quality and control, nonclinical and clinical testing, safety monitoring, and interactions with European and US regulators and payors.
Celdara Medical collaborates with recognized academic scientific leadership and their institutions to steward innovations from the lab through pre-clinical development performing necessary developmental activities to enable the launch of science into clinical application.
Full pipeline, including Ex-US Biotech partner information and terms are available under confidentiality.